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Interaction of CD95 ligand with its cognate receptor
CD95 induces apoptotic cell death. Alterations in
this pathway within tumor cells can result in escape
from apoptosis and from immune surveillance.
Melanoma cells recently were found to escape an
immune attack via high expression of CD95 ligand,
thereby inducing apoptosis of activated T lympho-
cytes. When screening four human melanoma cell
lines for expression of CD95 and CD95 ligand,
respectively, an inverse correlation was found, i.e.,
cells expressing high levels for CD95 ligand
(CD95Lhigh) were almost negative for CD95 and vice
versa. Since coexpression of CD95 and CD95 ligand
may lead to apoptosis by autocrine suicide or fratri-
cide, it was tested whether overexpression of CD95
in CD95Lhigh melanoma cells results in apoptotic cell
death. Upon transfection with a cytomegalovirus-
promoter-driven expression vector encoding the
CD95 gene, CD95Lhigh melanoma cells underwent
apoptosis at a much higher level than CD95Llow mel-
anoma cells. Apoptosis appeared to be due to the
activation of CD95 as cell death was inhibited by
cotransfection with a dominant negative mutant for
the CD95 signaling protein, Fas-associated protein
with death domain. Tumor progression of CD95Lhigh
melanoma cells transplanted into nude mice was sig-
ni®cantly reduced when recipient animals were
injected with liposomes containing the CD95 expres-
sion vector. As demonstrated by immunohistochem-
istry and TUNEL staining, in vivo transfected tumor
cells expressed CD95 and underwent apoptotic cell
death. Hence, this study indicates that delivery of the
CD95 gene inhibits tumor growth in vivo and thus
might be a therapeutic strategy to treat tumor cells
that express high levels of CD95 ligand. Key words:
apoptosis/CD95/gene delivery/melanoma/therapy. J Invest
Dermatol 115:1008±1014, 2000
T
he incidence of malignant melanoma has been
increasing in most countries over the last few decades.
In contrast to nonmelanoma skin cancer, the patho-
genesis of melanoma still remains an enigma on the
whole. Intermittent and intense sun exposure, how-
ever, especially in childhood may be one of the essential factors.
Malignant melanoma is one of the most aggressive tumors, causing
for example approximately 6500 deaths per year in the U.S.A.
(Johnson et al, 1995). Surgery is successful in primary melanoma,
but disseminated disease is usually resistant to conventional
treatment, which includes radiation and chemotherapy. Therefore
there is an urgent need for new and innovative concepts to treat
this malignant disease. Immunologic approaches including vaccina-
tion studies try to exploit the high antigenicity of melanomas and
have begun to yield the ®rst signs of success. Another promising
approach in innovative cancer therapy is to activate the
programmed cell death machinery in the tumor cells, thereby
inducing apoptotic cell death (Korsmeyer and Greenberg, 1998).
Apoptosis is not only essential for the development and the
maintenance of tissue homeostasis but also serves as an effective
mechanism by which harmful cells can be eliminated. Induction of
apoptosis allows the organism to get rid of infected cells but also of
tumor cells. Accordingly, resistance to apoptosis was identi®ed as a
crucial event in tumorigenesis. Apoptosis of tumor cells can be
initiated by triggering cell death receptors, leading to activation of
the intracellular apoptotic machinery (Korsmeyer and Greenberg,
1998). Among the many death receptors including TNF-R1,
TRAIL-R1, TRAIL-R2, and DR-3, CD95, also called Fas or
Apo-1, is one of the most potent transducers of apoptosis (Peter and
Krammer, 1998). Triggering of the CD95 molecule either by
agonistic antibodies or by the natural ligand, CD95L (FasL),
induces apoptosis (Nagata, 1997). Ligand binding causes trimeriza-
tion of CD95 and the trimerized cytoplasmic region then
transduces the signal by recruiting the adapter molecule FADD
(Fas-associated protein with death domain) which binds to CD95
via interaction of the death domain at its C terminus (Boldin et al,
1995; Chinnaiyan et al, 1995). The N-terminal region of FADD is
responsible for downstream signal transduction by recruitment of
the cysteine protease, caspase-8 (Muzio et al, 1996; Boldin et al,
1996). Subsequently activation of a cascade of downstream caspases
executes apoptotic cell death (Alnemri et al, 1996). Hence, cells
expressing high levels of CD95L can drive activated lymphocytes
that bear CD95 on their surface into apoptosis and thereby escape
an immune attack. Consequently, cells or organs expressing high
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levels of CD95L are able to acquire a kind of immune privileged
state (Bellgrau et al, 1995; Grif®th et al, 1995).
Recently, it was shown that melanoma cells can escape an
immune attack via expressing CD95L on their surface (Hahne et al,
1996). In metastatic lesions, CD95-expressing T lymphocytes were
found in close proximity to the tumor cells. Upon incubation with
CD95L-positive melanoma cells, apoptosis of CD95-sensitive
targets occurred. In addition, CD95L-positive murine melanoma
cells grew rapidly when transplanted into normal recipients,
whereas tumor progression was delayed when they were
transplanted into lpr mice which lack CD95. Hence, expression
of CD95L may contribute to the immune privileged state of
melanoma cells and thereby enable progressive growth. As
demonstrated recently in situ, the expression of CD95L appears
to be enhanced during progression of malignant melanoma (Maeda
et al, 1998). High expression of CD95L on melanoma cells was also
con®rmed by other groups (Sprecher et al, 1999; Terheyden et al,
1999); however, in these cases no signi®cant correlation between
CD95L expression in melanoma cells and apoptosis in melanoma
in®ltrating mononuclear cells was found. High levels of CD95L
expression were also found on cells derived from squamous cell
carcinomas of the head and neck (Gastman et al, 1999),
hepatocellular carcinomas (Strand et al, 1996), colon cancers
(O'Connel et al, 1996), astrocytoma (Saas et al, 1997), and liver
metastases of a colon adenocarcinoma (Shiraki et al, 1997).
Screening human melanoma cell lines for expression of CD95
and CD95L, respectively, we observed an inverse correlation of
these two molecules, i.e., cells expressing high levels for CD95L
(CD95Lhigh) were almost negative for CD95 and vice versa. Since it
was previously shown that coexpression of CD95 and CD95L may
lead to apoptosis by autocrine suicide or fratricide (Dhein et al,
1995; Friesen et al, 1996) we postulated that overexpression of
CD95 in CD95Lhigh melanoma cells should result in apoptotic cell
death. Upon overexpression of CD95, CD95Lhigh melanoma cells
underwent apoptosis at a much higher level than CD95Llow
melanoma cells. Accordingly, tumor progression of CD95Lhigh
melanoma cells transplanted into nude mice was signi®cantly
reduced when recipient animals were injected with liposomes
containing an expression vector encoding CD95. Hence, this study
indicates that in vivo overexpression of CD95 might be a
therapeutic strategy to treat tumor cells which express high levels
of CD95L.
MATERIALS AND METHODS
Reagents Antibodies (polyclonal rabbit IgG) directed against CD95L
and CD95, respectively, were purchased from Santa Cruz, Santa Cruz, CA.
An expression vector for CD95 was constructed by subcloning cDNA
encoding CD95 (kindly provided by S. Nagata, Osaka, Japan) into XhoI/
XbaI sites of pBKCMV vector (Stratagene, La Jolla, CA), which contains a
cytomegalovirus (CMV) promoter cassette. An expression vector of
dominant negative inhibitor of FADD was a kind gift from V.M. Dixit,
San Francisco (Chinnaiyan et al, 1995). An expression vector for cowpox
serpin CrmA was obtained from K. Schulze-Osthoff, MuÈnster, Germany.
The broad spectrum caspase inhibitor z-Val-Ala-Asp-CH2F (zVAD) was
purchased from Enzyme Systems Products (Livermore, CA). pSVb-
galactosidase vector was purchased from Stratagene.
Cells The human melanoma-derived cell lines G361, MeWo, p22, and
p38 were a kind gift from T. Horikawa, Kobe, Japan. Cells were
maintained in Eagle's modi®ed essential medium (MEM) supplemented
with 10% fetal bovine serum, 1% L-glutamine, and 1% antimycotic/
antibiotic solution in a humidi®ed atmosphere containing 5% CO2.
Western blot analysis Cells were harvested by use of a rubber
policeman and lyzed in RIPA buffer (10 mM Tris pH 8, 150 mM NaCl,
1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate
(SDS), 1 mM phenylmethylsulfonyl ¯uoride, 4 mg per ml aprotinine, 1 mM
sodium orthovanadate) for 15 min on ice. After centrifugation, supernatants
were collected, and the protein contents were measured with a BioRad
Protein assay kit (BioRad, Hercules, CA). Twenty micrograms of each
protein sample were subjected to 12% SDS-polyacrylamide gel
electrophoresis (PAGE) under reducing conditions, blotted to PVDF
membranes (Immobilon-p, Bedford, MA), and incubated with antibodies
directed against CD95 and CD95L, respectively. Signals were detected by
use of an ECL kit (Amersham, Buckinghamshire, U.K.). To monitor equal
loading of proteins, blots were reprobed with an antibody directed against
a-tubulin (Calbiochem, Cambridge, MA).
Immunohistochemistry Cells were seeded on Chamber slides (Nunc,
Roskilde, Denmark), ®xed in 4% paraformaldehyde 24 h later, and washed
three times in phosphate-buffered saline (PBS). Samples were then
incubated with a rabbit polyclonal IgG directed against CD95L or against
CD95 at 37°C for 80 min, washed three times in PBS at room temperature
each for 5 min, and incubated with ¯uorescein-isothiocyanate (FITC)
conjugated goat antibody directed against rabbit IgG (BioSource,
Camarillo, CA) at 37°C for 30 min. Samples were then extensively
washed ®ve times in PBS at room temperature each for 5 min, and
reactions were visualized under a ¯uorescence microscope.
Double immunostaining of melanoma cells implanted into nude mice
was performed by using mouse monoclonal IgG to CD95 (Novus
Molecular, San Diego, CA) and rabbit polyclonal IgG to CD95L
(incubation for 1 h at 37°C). After extensive washing with PBS,
rhodamine-conjugated antimouse IgG or FITC-coupled antirabbit IgG
were added. Samples were evaluated under a ¯uorescence microscope using
two different ®lters.
Transfection Cultured cells were cotransfected with 1 mg pSVb-
galactosidase vector along either with 1 mg of a CMV-promoter-driven
expression vector of CD95 (pCMV-CD95) or with its insertless control
vector (pBKCMV) using the Lipofectamine method (Life Technologies,
Gaithersburg, MD). Forty-eight hours after transfection, cells were ®xed in
PBS containing 2% paraformaldehyde, 0.2% glutaraldehyde at 4°C for
20 min and stained for 5 h with X-gal (100 mg per ml), 5 mM potassium
ferricyanide, 5 mM potassium ferrocyanide, and 1 mM MgCl2 in PBS.
Positive cells were microscopically analyzed for apoptosis according to the
method described by Bertin et al (1997) and Hsu et al (1995) with slight
modi®cations (Aragane et al, 1998). Apoptotic cells were differentiated as
blue rounded cells from intact living ¯at cells. Four random ®elds were
counted. Data are given as the percentage of living cells calculated
according to the formula (number of living cells per ®eld divided by
number of total cells per ®eld) 3 100.
In vivo gene delivery To generate an in vivo melanoma model, 1 3 105
MeWo cells were suspended in 100 ml fresh Eagle's MEM, and injected
subcutaneously into the back of nude mice (n = 6). When the diameter of
tumors reached 5 mm, in vivo injection of plasmids incorporated into
hemagglutinin virus of Japan (HVJ) liposomes was conducted. HVJ
liposomes were prepared as described previously (Kaneda et al, 1988;
Kaneda, 1994; Saeki et al, 1997). About 50 mg of plasmid DNA were
entrapped in 10 ml of liposome suspension. Approximately 500 ng of either
pBKCMV or pCMV-CD95 encapsulated into HVJ liposomes (100 ml)
were directly injected into the tumors twice a week. Tumor size and
weight of the mice were monitored once a week. Twenty-eight days after
the ®rst injection mice were sacri®ced, and tumors were excised, weighed,
and snap frozen in liquid nitrogen until being further processed.
TUNEL assay Tumor samples were ®xed in 4% paraformaldehyde in
PBS (pH 7.4) at room temperature for 10 min. Samples were then rinsed in
PBS three times. TUNEL staining was performed using In Situ Cell Death
Detection kitTM (Boehringer Mannheim, Mannheim, Germany). Brie¯y,
®xed samples were reacted with TUNEL reaction buffer containing TdT at
37°C for 60 min and washed three times at room temperature each for
5 min. Samples were evaluated under a ¯uorescence microscope.
RESULTS
Inverse correlation of the expression of CD95 and CD95L in
different melanoma cell lines The constitutive expression of
CD95L in different melanoma cell lines was determined by western
blot analysis. Proteins were extracted from unstimulated MeWo,
p38, G361, and p22 cells, and subjected to western blot analysis
using an antibody directed against CD95L. As depicted in Fig 1,
the melanoma cell lines MeWo and p38 expressed high levels of
CD95L (lanes 2 and 4), whereas only minimal amounts were
detectable in G361 and p22 cells (lanes 1 and 3). The inverse pattern
was found for the expression of CD95: G361 and p22 cells
expressed high amounts of CD95 protein, while MeWo and p38
did not. These data were con®rmed by immuno¯uorescence
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analysis which revealed strong staining for CD95L in MeWo and
p38 cells, whereas G361 and p22 cells were almost negative (Fig 2).
Hence, MeWo and p38 were referred to as CD95Lhigh cells and
G361 and p22 as CD95Llow cells. Immunohistochemical staining
using an antibody directed against CD95 revealed the same inverse
expression pattern for CD95; melanoma cells expressing high levels
of CD95L did not stain for CD95 and vice versa (Fig 2). The
different expression of CD95 was also con®rmed by treating the
cells with recombinant CD95L. CD95L induced signi®cant
apoptosis in G361, but not in MeWo cells (data not shown). For
the further studies, MeWo cells were used as CD95Lhigh cells and
G361 as CD95Llow cells.
Induction of CD95 expression by transfection Since MeWo
cells express high amounts of CD95L but only minimal numbers of
CD95 receptors we were interested whether CD95Lhigh cells
undergo apoptosis upon expression of signi®cant amounts of
CD95. To address this question, a CMV-promoter-driven
expression vector for CD95 was ®rst transfected into MeWo and
G361cells. To avoid possible apoptotic cell death by just
transfecting the CD95 expression vector, in the initial studies an
expression vector encoding the antiapoptotic cowpox serpin CrmA
was cotransfected (Tewari et al, 1995). Cells were harvested 48 h
later, proteins were extracted, and western blot analysis was
performed using an antibody directed against CD95. As shown in
Fig 3, signi®cant levels of CD95 protein were detectable in both
MeWo and G361 transfected with the CD95 encoding construct,
while after mock transfection constitutive expression was only
found in G361 (lane 1) but not in MeWo cells (lane 3).
Overexpression of CD95 causes stronger apoptosis in
CD95Lhigh cells than in CD95Llow cells To address the initial
question whether ectopical expression of CD95 leads to apoptosis
of melanoma cells, the CD95 expression vector was transfected into
MeWo and G361 cells. To determine the ef®cacy of transfection,
an expression vector encoding b-galactosidase was cotransfected.
Sixteen hours later cells were ®xed and the viability of b-
galactosidase-expressing cells was evaluated as described previously
(Hsu et al, 1995; Bertin et al, 1997; Aragane et al, 1998). Mock-
transfected cells did not change their morphology, still appearing
dendritic. In contrast, the majority of CD95-transfected MeWo
cells lost their original dendritic morphology and became rounded,
indicative of apoptosis. In contrast, the apoptosis rate in CD95-
transfected G361 cells was much less. Quantitative evaluation of
apoptosis revealed a signi®cantly enhanced death rate in CD95-
transfected MeWo cells compared to CD95-transfected G361 cells
(Fig 4).
To study whether sensitivity of CD95-transfection-induced
apoptosis is dependent on the amounts of CD95 expressed, both
CD95Lhigh and CD59Llow cells were transfected with increasing
amounts of CD95 expression vector ranging from 0.25 to 1 mg. For
comparison, we also used the human trichilemmoma cell line K-
TL-1 (Kanzaki et al, 1981), which expresses only minimal amounts
of CD95L as detected by immunohistochemical staining (data not
shown). Upon transfection with 1 mg expression vector for CD95,
almost all MeWo cells underwent apoptosis (note that only
successfully transfected cells were counted), while only around
50% apoptotic cells were observed in the G361 group (Fig 4).
Transfection with the insertless mock construct did not have any
impact on cell viability (data not shown). Although the ef®cacy of
the induction of apoptosis declined with decreasing amounts of the
CD95 expression vector transfected, more than 80% of MeWo cells
became apoptotic upon transfection with 0.25 mg. In contrast, only
25% apoptotic cells were observed in G361 and K-TL-1 cells.
Hence, the susceptibility to CD95-transfection-induced apoptosis
was signi®cantly enhanced in CD95Lhigh cells in comparison with
CD95Llow cells. These data indicate that the ef®cacy of inducing
apoptosis by overexpressing CD95 is critically dependent on the
amounts of CD95L expressed by the respective cells.
Apoptosis induced by transfection with CD95 is inhibited by
CrmA, a dominant negative mutant of FADD, or
zVAD To rule out the unlikely possibility that just the
transfection of such high molecular weight DNA like CD95 is
toxic and thus interferes with cell viability, MeWo cells were
cotransfected with either an expression vector encoding CrmA or a
dominant negative mutant of FADD. As demonstrated in Fig 5,
CD95-mediated apoptosis induced by overexpressing CD95 was
Figure 1. Inverse expression of CD95L and CD95 by human
melanoma cells. Proteins were extracted from untreated G361 (lane 1),
MeWo (lane 2), p22 (lane 3), and p38 cells (lane 4) and fractionated in 12%
SDS-PAGE. Western blot analysis was performed using antibodies directed
against CD95L, CD95, and a-tubulin.
Figure 2. Inverse expression of CD95L and
CD95 detected by immunohistochemistry.
One day before immunostaining, cells (1 3 103)
were seeded on chamber slides. After permeabili-
zation of membranes, cells were stained by an in-
direct immuno¯uorescence technique using
antibodies directed against CD95L and CD95, re-
spectively. After incubation with FITC-labeled
goat antirabbit IgG samples were evaluated by
¯uorescence microscopy.
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signi®cantly reduced by cotransfection with either CrmA or the
dominant mutant of FADD. Accordingly, transfection-induced cell
death was remarkably reduced by the broad spectrum inhibitor of
caspases, zVAD.
In vivo delivery of CD95 expression vector via HVJ
liposomes reduces CD95Lhigh-expressing tumors To
elucidate whether transfection with CD95 inhibits growth of
CD95Lhigh tumor cells in vivo, MeWo cells (1 3 105) were
transplanted by subcutaneous injection into the back of nude
mice. Approximately 1 wk later when tumors had reached 5 mm in
diameter, the expression vector of CD95 (pCMV-CD95) or the
insertless mock plasmid (pBKCMV) were injected directly into the
tumors twice per week. To enable penetration into the cells, both
plasmids were encapsulated into HVJ liposomes which have been
reported to be effective in introducing foreign genes in vivo
(Kaneda, 1999; Kaneda et al, 1999). The size of tumors was
measured once a week. To monitor ef®cacy of in vivo transfection,
a b-galactosidase expression vector was injected once into
melanomas transplanted onto nude mice. Three days later, tumors
were excised and b-galactosidase expression was visualized by
staining tumor samples with X-gal. A signi®cant number of
melanoma cells expressed b-galactosidase as demonstrated by blue
stained cells (Fig 6a, insert). While tumors grew progressively in the
mock-injected group, introduction of the CD95 expression vector
signi®cantly delayed tumor growth as determined by tumor size.
Mice were sacri®ced 28 d after the ®rst injection, and tumors were
excised and weighed. Tumors obtained from CD95-treated animals
were signi®cantly reduced in their weight compared with tumors of
mock-treated animals (Fig 6b).
To determine whether inhibition of tumor growth in vivo is due
to induction of apoptosis via upregulated CD95, the CD95
expression vector was injected into MeWo tumors which had been
transplanted into nude mice 7 d earlier. Tumors were excised 3 d
after injection and double immunostaining using antibodies
directed against CD95 and CD95L, respectively, was performed.
In accordance with the in vitro data, in vivo transplanted MeWo cells
expressed high levels of CD95L but not CD95 (Fig 7). In contrast,
cells became CD95 positive upon injection of the CD95 plasmid,
while CD95L expression was not affected. Together, these ®ndings
indicate that injection of CD95 plasmid encapsulated in HVJ
liposomes is an effective method for expressing CD95 in vivo.
To address whether reduced growth is due to induction of
apoptosis, samples were subjected to immunohistochemistry for
CD95 and TUNEL staining. In mock-injected tumors in which
only marginal expression of CD95 was found, no TUNEL-positive
cells were detected (Fig 8). In contrast, in areas that were positive
for CD95 due to injection of the CD95 plasmid the majority of
cells became apoptotic as shown by TUNEL positivity. This
indicates that in vivo injection of a CD95 expression vector into
CD95L-expressing tumor cells inhibits tumor growth via induction
of apoptosis.
DISCUSSION
Cancer cells escape immune clearance in several ways. These
include avoidance of immune recognition by the loss of antigenic
structures or by the downregulation of accessory molecules, or
inhibition of an immune response by the release of immunosup-
pressive molecules including cytokines or gangliosides (KoÈck et al,
1991; Bergelson, 1993). Besides these evasive strategies tumor cells
are able to actively disrupt an immune response. In this context, the
expression of CD95L has been recognized as a novel mechanism to
suppress an immune attack, since through this route tumor cells can
deliver a death signal to CD95-positive target cells (Walker et al,
1997). Using melanoma cell lines, Hahne et al were the ®rst to
show in vivo that tumor cells use the expression of CD95L to escape
immune rejection (Hahne et al, 1996).
Melanoma cells do not express high levels of CD95L in
general, however. Of the four melanoma cell lines tested in this
Figure 4. Cells expressing CD95L are more susceptible to apoptosis
induced by overexpression of CD95. G361, MeWo, and KTL-1 cells
were transfected with different concentrations of the CD95 expression
vector. Cells were cotransfected with b-galactosidase and evaluated for
apoptosis. Living dendritic-shaped blue cells and apoptotic rounded blue
cells were counted in four independent microscopic ®elds and the
percentage of apoptotic cells was calculated. Experiments were repeated
three times; the data shown represent one of those.
Figure 5. Inhibition of apoptosis induced by overexpression of
CD95 in MeWo cells. MeWo cells (3 3 105) were transfected with an
expression vector for CD95 along with constructs expressing either CrmA
or a dominant negative mutant of FADD. In addition, cells transfected with
CD95 only were cultured in the presence of 20 mM zVAD. Twenty-four
hours later, cells were evaluated for apoptosis. Experiments were repeated
three times; the data shown represent one of those.
Figure 3. Expression of CD95 in MeWo and G361 cells. One day
before transfection, cells were seeded on culture dishes at a density of
1 3 106. Twenty-four hours later, cells were transfected either with an
expression vector encoding CD95 (lanes 2, 4) or with an insertless control
plasmid (lanes 1, 3) using the Lipofectamine method. To avoid induction of
apoptosis by overexpression of CD95, cells were cotransfected with an
expression plasmid for CrmA. Forty-eight hours after transfection, proteins
were extracted and subjected to western blot analysis using an antibody
directed against CD95. Lanes 1, 2, G361; lanes 3, 4, MeWo.
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study only two (MeWo, p38) expressed CD95L, while the
other two lines (G361, p22) were CD95L negative.
Interestingly, the CD95L-positive melanoma cell lines did not
express CD95. The absence of CD95 may represent an
additional advantage for a tumor cell to survive and to progress
(SchroÈter et al, 2000). The mutually exclusive expression of
CD95 and CD95L observed in the four cell lines tested,
however, must not be regarded as a general phenomenon since
it could be representative only for selected cell lines. Ferrarini
et al and Ugurel et al found coexpression of CD95 and CD95L
on melanoma cells without any impact on cell survival. This
resistance may be due to overexpression of antiapoptotic
molecules (Ugurel et al, 1999) or alterations in the CD95-
triggered signaling cascade (Ferrarini et al, 1999).
Several tumor cells including glioma, rhabdomyosarcoma,
melanoma, colon cancer, and ovarian cancer (Yonehara et al,
1989; Morimoto et al, 1993; Weller et al, 1994; Owen-Schaub et al,
1998) were found to express CD95 at different levels. Such cells are
principally susceptible for being killed through this pathway, e.g.,
by cytotoxic T cells that carry CD95L on their surface. In addition,
they should be susceptible to therapies which target CD95, e.g.,
application of agonistic anti-CD95-antibodies (Weller et al, 1994).
Hence, development of resistance to CD95-mediated apoptosis
may be an important event during tumor progression. CD95
resistance can be achieved by secretion of soluble CD95 that traps
CD95L (Cheng et al, 1994), by downregulation of CD95 (Weller
et al, 1994), or by mutating CD95 (Shin et al, 1999). The latter
possibility was recently reported by Shin et al who observed that
somatic alterations of the CD95 gene in the cytoplasmic region
might lead to the loss of its apoptotic function. In addition, loss or
downregulation of CD95 expression may represent a further
advantage for tumor cells which express high levels of CD95L,
since coexpression of CD95 and CD95L may result in autocrine
suicide or fratricide (Dhein et al, 1995). Certain chemotherapeutic
drugs appear to make use of this pathway (Friesen et al, 1996).
Taken together, enhanced expression of CD95L and loss of CD95
expression may support aggressive behavior of tumor cells.
The molecular mechanism by which MeWo and p38 cells
downregulate CD95 expression remains to be determined. In this
context it is important to mention that oncogenic Ras recently was
found to downregulate CD95 at the transcriptional level, most
likely through DNA methylation (Peli et al, 1999). This
observation indicated that Ras not only promotes proliferation by
its oncogenic activity, but also confers this effect by protecting cells
from CD95L-mediated apoptosis.
When tumor cells express CD95 and provided that the signaling
pathway is not altered, induction of apoptosis via the CD95
pathway appears as an attractive strategy to treat these cancers.
Application of agonistic CD95 antibodies is problematic, however,
as, due to the ubiquitous expression of CD95 on normal cells and
tissues, injection of CD95 antibodies is toxic, e.g., due to fulminant
hepatic failure (Lacronique et al, 1996). In addition, as mentioned
above, many tumor cells lose the CD95 receptor on their surface
during progression. Since coexpression of CD95 and CD95L can
cause cell death either by autocrine suicide or fratricide (Dhein et al,
1995; Friesen et al, 1996), we were interested to study whether
CD95 gene delivery is a feasible route to eliminate melanoma cells
which express CD95L but not its cognate receptor CD95. To
address this issue, we ®rst introduced a CMV-driven expression
vector encoding CD95 into MeWo and G361 cells. Spontaneous
apoptosis was observed in both cell lines; however, the apoptosis
rate was signi®cantly higher in the transfected MeWo cells. Since
G361 cells do not express CD95L, spontaneous apoptosis may be
attributed just to the overexpression of CD95. Previous studies
have demonstrated that mere overexpression of the CD95 receptor
may suf®ce to cause apoptosis (Liu et al, 1996). As the apoptosis rate
was signi®cantly higher in MeWo cells, however, we anticipated
that this is due to the interaction of ectopically expressed CD95 and
constitutively expressed CD95L. To further support this anticipa-
tion, in preliminary experiments we tested whether transfected
MeWo cells can be rescued by adding neutralizing anti-CD95
antibodies. Surprisingly, this approach did not alter the survival
signi®cantly. We do not have an explanation for this phenomenon
yet; however, it may be that we have not yet found the optimal
conditions concerning antibody concentrations or kinetics. Studies
are ongoing to try to clarify this issue.
Nevertheless, the in vitro observations supported our hypothesis
that CD95L expression may sensitize cells to undergo apoptosis
following CD95 gene delivery. To test whether this approach is
also effective in vivo, we transplanted MeWo cells into nude mice.
Since nude mice are immunode®cient, human melanoma cells are
not rejected and grow progressively. In vivo gene delivery has been
Figure 6. In vivo transfection with CD95 prevents tumor progres-
sion. MeWo cells (1 3 105) were transplanted into nude mice (n = 6) by
subcutaneous injection. When tumors had reached the size of 5 mm in
diameter, 0.5 mg pCMVCD95 (d) or 0.5 mg pBKCMV (s), both
encapsulated into HVJ liposomes along with the b-galactosidase gene,
were injected into the tumors twice a week. Ef®cacy on in vivo transfection
was evaluated by staining tissue samples for X-gal (a, insert). Tumor sizes
were measured at days 0, 7, 14, 21, and 28 (a). On day 28 tumors were
excised and weighed. Tumor weights (mean 6 SD) are shown on the y axis
(mg) (b).
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performed previously using several different methods (Bonnekoh
et al, 1995; Hengge et al, 1995). We used the HVJ liposome
method, which involves the entrapment of DNA and high-
mobility group 1 protein within liposomes and the use of
ultraviolet-inactivated HVJ to enhance liposome fusion with cell
membranes. This procedure has already been utilized successfully
for in vivo gene delivery to various types of tissue (Kaneda et al,
1988). Sawamura et al recently used the HVJ method to transfer the
herpes simplex virus thymidine kinase gene into murine squamous
cell carcinomas (Sawamura et al, 1997). Local injection of HVJ
liposomes followed by administration of ganciclovir to mice
resulted in tumor growth inhibition. As demonstrated in this
study, CD95Lhigh melanoma cells that were injected with liposomes
containing the empty vector grew progressively, whereas tumor
growth was completely stopped upon injection of liposomes
containing the CD95 construct. In vivo delivery of the CD95 gene
was successful since tumor cells located in the injected areas were
found to be CD95 positive by immunohistochemistry. Inhibition
of tumor growth appears to be due to the induction of apoptosis
since numerous TUNEL-positive cells were detectable in the
injected areas. Most of the TUNEL-positive cells also expressed
CD95, indicating that apoptosis induced by transfer of the CD95
gene may be due to autocrine suicide.
Taken together, these data indicate, as already proposed recently
(SchroÈter et al, 2000), that CD95 gene transfer may serve as a
strategy to induce apoptosis selectively in tumor cells that express
high levels of CD95L. Of course, a suicide gene therapy alone as
used in this study would be insuf®cient to treat melanoma, since
disseminated metastasis, the most critical aspect in terms of survival,
would not be affected. Combination with other strategies, e.g.,
immunotherapeutic approaches, might overcome this problem. An
alternative would be the systemic delivery of suicide genes like
CD95 under control of promoters of melanoma-speci®c genes.
Although these problems still remain to be solved, this study
provides the proof in principle that in vivo delivery of the CD95
gene can be used to eradicate CD95L-expressing tumors.
Accordingly, local injection of HVJ liposomes containing CD95
DNA could be useful for the treatment of disseminated cutaneous
melanoma metastasis that cannot be removed surgically. One has to
bear in mind, however, that this strategy will only work if the
apoptotic pathway is not blocked, e.g., by overexpression of
antiapoptotic molecules, like FLIP, bcl-2, bcl-x, or others.
It was recently shown that basal cell carcinomas, another kind of
skin cancer, express high amounts of CD95L (Buechner et al, 1997;
Gutierrez-Steil et al, 1998). Regression of basal cell carcinomas by
intralesional interferon-a treatment seems to be due to upregula-
tion of CD95, thereby causing CD95/CD95L-induced suicide
(Buechner et al, 1997). Hence, CD95 gene delivery should have
the same therapeutic effect. Liposomes are known to penetrate the
corneal layer of the skin and to accumulate in the epidermis. As
demonstrated recently for DNA repair enzymes (T4N5 endonu-
clease, photolyase), liposomes can deliver encapsulated proteins into
Figure 7. In situ detection of CD95 after in
vivo transfection. MeWo cells (1 3 105) were
transplanted into nude mice (n = 6) by subcuta-
neous injection. When tumors had reached the
size of 5 mm in diameter, in vivo transfection with
CD95 or with the mock construct was performed
as described in Fig 6. Two days later, tumors were
excised and immunohistochemistry was performed
using an FITC-conjugated antibody against
CD95L and a phycoerythrin-conjugated antibody
against CD95.
Figure 8. In vivo transfection of MeWo cells
with CD95 results in apoptosis. MeWo cells
(1 3 105) were transplanted into nude mice (n = 6)
by subcutaneous injection. When tumors had
reached the size of 5 mm in diameter, in vivo
transfection with CD95 or with the mock con-
struct was performed as described in Fig 7. Two
days later, tumors were excised. Tissue sections
were stained for CD95 and for apoptotic cells
using the TUNEL method.
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cells of the skin in vitro and in vivo (Yarosh et al, 1994; Kulms et al,
1999). Although it remains to be determined whether topically
applied liposomes can be used to deliver genes in vivo into the skin
as effectively as proteins, it is tempting to speculate on the
therapeutic potential of topical CD95 gene delivery for the
treatment of skin cancer by this route.
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